Association Between Lipoprotein(a) and Peripheral Arterial Disease in Coronary Artery Bypass Grafting Patients

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Mar 10

PMID 36896666

Authors

Cheng Yi

Gao Junyi

Liu Fengju

Zhao Qing

Chen Jie

Affiliations

Soon will be listed here.

Abstract

Objective: Peripheral arterial disease (PAD) affects a large population and is associated with various adverse clinical outcomes. Lipoprotein(a) has proatherogenic properties and is associated with PAD incidence and severity. The aim of this study is to explore the association between LP(a) and PAD in coronary artery bypass grafting (CABG) patients.

Methods: A total of 1001 patients were included and divided into two groups: low Lp(a) group [LP(a) < 30 mg/dL] and high Lp(a) group [LP(a) ≥ 30 mg/dL]. A comparison of PAD incidence diagnosed by ultrasound was made between the groups. Multivariate logistic regression was conducted to explore the risk factors for PAD. During the analysis, the influence of diabetes mellitus (DM) and gender on LP(a) serum level was taken into consideration.

Results: DM history (odds ratio [OR], 2.330, p = .000 for males; OR, 2.499, p = .002 for females) and age (OR, 1.101, p = .000 for males; OR, 1.071, p = .001 for females) were risk factors for PAD. LP(a) ≥ 30 mg/dL was a risk factor for PAD only in female patients (OR, 2.589, p = .003), while smoking history was a risk factor only in male patients (OR, 1.928, p = .000). LP(a) level was not associated with PAD severity in DM patients of both gender. As for female patients without DM, PAD was more severe in the high LP(a) group.

Conclusions: In CABG patients, DM history and age were risk factors for PAD. But a high level of LP(a) was a significant risk factor only in female patients. In addition, we are the first to propose a gender deviation in the correlation between LP(a) serum level and severity of PAD diagnosed by ultrasound.

Citing Articles

Ultrasound-based prevalence of polyvascular disease and its association with adverse outcome in patients undergoing coronary artery bypass grafting.

Gao J, Cheng Y Sci Prog. 2024; 107(4):368504241297206.

PMID: 39523630 PMC: 11552031. DOI: 10.1177/00368504241297206.

Correlation between circulating lipoprotein(a) levels and cardiovascular events risk in patients with type 2 diabetes.

Gu J, Huang J, Wang K, Yin Y, Fang J, Zhang A Heliyon. 2024; 10(17):e37415.

PMID: 39296136 PMC: 11408807. DOI: 10.1016/j.heliyon.2024.e37415.

The Role of Lipoprotein(a) in Peripheral Artery Disease.

Pavlatos N, Kalra D Biomedicines. 2024; 12(6).

PMID: 38927436 PMC: 11200468. DOI: 10.3390/biomedicines12061229.

Smoking as a risk factor for lower extremity peripheral artery disease in women compared to men: A systematic review and meta-analysis.

Xu Y, Pouncey A, Zhou Z, Woodward M, Harris K PLoS One. 2024; 19(4):e0300963.

PMID: 38656947 PMC: 11042699. DOI: 10.1371/journal.pone.0300963.

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?.

Tsioulos G, Kounatidis D, Vallianou N, Poulaki A, Kotsi E, Christodoulatos G Int J Mol Sci. 2024; 25(6).

PMID: 38542510 PMC: 10971284. DOI: 10.3390/ijms25063537.

References

Yi C, Junyi G, Fengju L, Qing Z, Jie C . Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients. Clin Cardiol. 2023; 46(5):512-520. PMC: 10189068. DOI: 10.1002/clc.24003. View

Tendera M, Aboyans V, Bartelink M, Baumgartner I, Clement D, Collet J . ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and.... Eur Heart J. 2011; 32(22):2851-906. DOI: 10.1093/eurheartj/ehr211. View

Rasouli M, Mohseni Kiasari A . Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease. Clin Chem Lab Med. 2008; 46(5):667-73. DOI: 10.1515/CCLM.2008.137. View

Whelan J, Barry M, MOIR J . Color flow Doppler ultrasonography: comparison with peripheral arteriography for the investigation of peripheral vascular disease. J Clin Ultrasound. 1992; 20(6):369-74. DOI: 10.1002/jcu.1870200602. View

Hiatt W, Goldstone J, Smith Jr S, McDermott M, Moneta G, Oka R . Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation. 2008; 118(25):2826-9. DOI: 10.1161/CIRCULATIONAHA.108.191171. View

Qasim A, Martin S, Mehta N, Wolfe M, Park J, Schwartz S . Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol. 2010; 150(1):17-21. PMC: 3132301. DOI: 10.1016/j.ijcard.2010.02.021. View

Criqui M, Fronek A, Barrett-Connor E, Klauber M, Gabriel S, Goodman D . The prevalence of peripheral arterial disease in a defined population. Circulation. 1985; 71(3):510-5. DOI: 10.1161/01.cir.71.3.510. View

Kostner K, Kostner G . Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus. Int J Mol Sci. 2022; 23(7). PMC: 8998850. DOI: 10.3390/ijms23073584. View

Virani S, Alonso A, Benjamin E, Bittencourt M, Callaway C, Carson A . Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020; 141(9):e139-e596. DOI: 10.1161/CIR.0000000000000757. View

10.

Cook N, Mora S, Ridker P . Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. J Am Coll Cardiol. 2018; 72(3):287-296. PMC: 6277983. DOI: 10.1016/j.jacc.2018.04.060. View

11.

Danesh J, Collins R, Peto R . Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102(10):1082-5. DOI: 10.1161/01.cir.102.10.1082. View

12.

Cheng S, Ting A, Wong J . Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg. 1997; 14(1):17-23. DOI: 10.1016/s1078-5884(97)80220-1. View

13.

Steg P, Bhatt D, Wilson P, DAgostino Sr R, Ohman E, Rother J . One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297(11):1197-206. DOI: 10.1001/jama.297.11.1197. View

14.

Khera A, Everett B, Caulfield M, Hantash F, Wohlgemuth J, Ridker P . Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2013; 129(6):635-42. PMC: 3946056. DOI: 10.1161/CIRCULATIONAHA.113.004406. View

15.

Criqui M, Matsushita K, Aboyans V, Hess C, Hicks C, Kwan T . Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(9):e171-e191. PMC: 9847212. DOI: 10.1161/CIR.0000000000001005. View

16.

Tzoulaki I, Murray G, Lee A, Rumley A, Lowe G, Fowkes F . Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007; 28(3):354-62. DOI: 10.1093/eurheartj/ehl441. View

17.

Yanaka K, Akahori H, Imanaka T, Miki K, Yoshihara N, Kimura T . Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions. J Atheroscler Thromb. 2020; 28(5):555-561. PMC: 8193776. DOI: 10.5551/jat.56457. View

18.

Cybulska B, Klosiewicz-Latoszek L, Penson P, Banach M . What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?. Prog Cardiovasc Dis. 2020; 63(3):219-227. DOI: 10.1016/j.pcad.2020.04.004. View

19.

Lamina C, Kronenberg F . The mysterious lipoprotein(a) is still good for a surprise. Lancet Diabetes Endocrinol. 2014; 1(3):170-2. DOI: 10.1016/S2213-8587(13)70085-8. View

20.

Li J, Ma C, Zhao D, Yan X . Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement. JACC Asia. 2022; 2(6):653-665. PMC: 9700018. DOI: 10.1016/j.jacasi.2022.08.015. View